TEST BANK -RAUS RESPIRATORY CARE PHARMACOLOGY 11th EDITION (GARDENHIRE,2023)/ALL CHAPTERS S 1-23(COMPLETE GUIDE)

TEST BANK FOR RAUS RESPIRATORY CARE
n n n n n



nPHARMACOLOGY11th EDITION BY GARDENHIRE/ALL
n n n n



nCHAPTERS S 1-23
n n

,CH 01: Introduction to Respiratory Care Pharmacology
n n n n n n n

Gardenhire: Rau’s Respiratory Care Pharmacology, 11th
n n n n n n

Edition
n




MULTIPLE nRESPONSE

1. The nlisting nof na ndrug nand nthe namount n of ndrug nare nfound nin nwhich npart nof na nprescription?
a. Superscription
b. Inscription
c. Subscription
d. Transcription n(signature)
PRECISE nANSWER:-B
Reasoning n:->>>The nsuperscription ndirects nthe nregistered npharmacist nto ntake nthe ndrug nlisted nand nprepare
nthe ndrug; nthe ninscription nlists nthe nname nand nquantity nof nthe ndrug nbeing nprescribed; nthe nsubscription

nprovides ndirections nto nthe nregistered npharmacist n for npreparing nthe n drug; nand nthe ntranscription, nor

nsignature, nis nthe n information nthe nregistered npharmacist n writes non nthe n label nas n instructions nto nthe npatient.




REFERENCE: n p. n7

2. If ngeneric nsubstitution nis npermitted non na nprescription:
a. drug nfrom nonly none nmanufacturer nmust nbe ngiven.
b. drug nformulation nmay nbe nchanged nby nthe nregistered npharmacist.
c. any nmanufactured nbrand nof nthe ndrug nlisted nmay nbe ngiven.
d. drug nstrength nmay nbe nchanged nby nthe nregistered npharmacist.
PRECISE nANSWER:-C
Reasoning n:->>>A ngeneric nsubstitution nallows nany nbrand nof na ndrug nto nbe ngiven, nbut nthe nregistered
npharmacist nmay nnot nchange na ndrug nformulation nwithout nspecific npermission nfrom nthe nprescribing

nphysician. nA nphysician ncan nindicate nto nthe nregistered npharmacist nthat ngeneric nsubstitution nis npermitted nin

nthe nfilling nof nthe nprescription. nIn nsuch na ncase, nthe nregistered npharmacist nmay nprovide nany nmanufacturer’s

nversion nof nthe nprescribed ndrug, nrather nthan na nspecific nbrand. nHowever, nthe nregistered npharmacist nmay nnot

nchange nthenstrength nof na ndrug nwithout nspecific npermission nfrom nthe nprescribing nphysician.




REFERENCE: n p. n8

3. The nstudy nof ndrug, nincluding ntheir norigin, nproperties, nand n interactions nwith nliving norganisms, n is nknown nas
a. pharmacogenetics.
b. pharmacology.
c. therapeutics.
d. toxicology.
PRECISE nANSWER:-B
Reasoning:->>>Pharmacogenetics nis nthe nstudy nof nthe ninterrelationship nof ngenetic ndifferences nand ndrug
neffects. nPharmacology nis nthe nstudy nof ndrug n(chemicals), nincluding ntheir norigin, nproperties, nand ninteractions

nwith nliving norganisms.

Therapeutics nis nthe nart nof ntreating nillness nwith ndrug. nToxicology nis nthe nstudy nof ntoxic nsubstances nand ntheir
npharmacologic nactions, n including nantidotes nand n poison ncontrol.




REFERENCE: n p. n3

4. The nbrand nname ngiven nto na ndrug nby na nparticular nmanufacturer nis nknown nas nthe ndrug’s
a. chemical nname.
b. generic nname. nc.official nname. nd.trade nname.
PRECISE nANSWER:-D
Reasoning:->>>The nchemical nname nindicates nthe ndrug’s nchemical nstructure. nThe ngeneric nname nis nassignednby

,the nUnited n States
n

, Adopted nName nCouncil nand nis nusually nbased nloosely non nthe ndrug’s nchemical nstructure. n The nofficial nname n isnthe
name ngiven nto nthe ngeneric nname nonce na ndrug nbecomes nfully napproved nfor ngeneral nuse nand nis nadmitted nto
nthe nUnited nStates nPharmacopeia–National nFormulary. nThe ntrade nname nis nthe nbrand, nor nproprietary, nname

ngiven nby na nparticular n manufacturer. nFor nexample, nthe ngeneric n drug nalbuterol nis ncurrently nmarketed nby

nSchering-nPlough nas nProventil
® nand nby nGlaxoSmithKline nas nVentolin®.


REFERENCE: n p. n5

5. To nfind nofficial ninformation nabout n drug n(according nto nthe nFDA), n you nneed nto ngo nto nthe
a. Physician’s nDesk nReferenceerence n(PDR).
b. Basic n& nClinical nPharmacology.
c. United nStates nPharmacopeia–National nFormulary n(USP-NF).
d. Goodman n& nGilman’s nThe nPharmacological nBasis nof nTherapeutics.
PRECISE nANSWER:-C
Reasoning:->>>Because nthe nPDR nis nprepared nby ndrug nmanufacturers nthemselves, nit nmay nbe nlacking nin
nobjectivity. nBasic n& nClinical nPharmacology ncovers nonly ngeneral npharmacologic nprinciples nand ndrug

nclasses. nGoodman n& nGilman’s nThe nPharmacological nBasis nof nTherapeutics ncovers nonly ngeneral

npharmacologicnprinciples nand ndrug nclasses. nThe nUSP-NF nis na nbook nof nstandards ncontaining ninformation

nabout ndrugs, ndietary nsupplements, nand nmedical ndevices. nThe nU.S. nFood nand nDrug nAdministration n(FDA)

nconsiders nthis nbook nthe nofficial nstandard nfor n drug nmarketed nin nthe nUnited nStates.



REFERENCE: n p. n5



6. Drug nmay nbe nobtained nfrom nwhich nof nthe nfollowing nsources?
a. Plants
b. Animals
c. Minerals
d. Plants, nanimals, nand nminerals
PRECISE nANSWER:-D
Reasoning:->>>Drug nmay nbe nobtained nfrom nplants n(e.g., ndigitalis), nanimals n(e.g., ninsulin), nand nmineralsn(e.g.,
nmagnesium nsulfate).




REFERENCE: n p. n5

7. The nbranch nof nthe nU.S. ngovernment n responsible nfor nthe nprocess nof napproving ndrug nfor nclinical nuse n is nthe
a. USAN nCouncil.
b. FDA.
c. USP-NF.
d. PDR.
PRECISE nANSWER:-B
Reasoning:->>>The nUnited nStates nAdopted nName n (USAN) nCouncil nis nresponsible nfor nassigning na ngeneric
nname nto na nchemical nthat nappears nto nhave ntherapeutic nuse. nThe nU.S. nFood nand nDrug nAdministration n(FDA)

nis nresponsible nfor nthe nprocess nof napproving ndrug nfor nclinical nuse. nThe nprocess nby nwhich na nchemical

nmovesnfrom nthe nstatus nof na npromising npotential ndrug nto none nfully napproved nby nthe nFDA nfor ngeneral nclinical

nuse n is,non naverage, nlong, ncostly, nand ncomplex. nCost n estimates nvary, nbut nin nthe n1980s nit ntook n an naverage nof

n13 nto n15 nyearsnfrom nchemical nsynthesis nto nmarketing napproval nby nthe nFDA, nwith na ncost nof n$350 nmillion nin

nthe nUnited nStates.

The nUSP-NF nis na nbook
of nstandards nfor ndrugs, ndietary nsupplements, nand nmedical ndevices. nThe nPDR nis na nsource nof ndrugninformation
nprepared nby ndrug n manufacturers.




REFERENCE: n p. n4